BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: Is gemcitabine still the standard? World J Gastroenterol 2012; 18(8): 736-745 [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736]
URL: https://www.wjgnet.com/1007-9327/full/v18/i8/736.htm
Number Citing Articles
1
Kolaparthi Venkatasubbarao, Lindsay Peterson, Shujie Zhao, Ping Hill, Lin Cao, Qing Zhou, Steffan T Nawrocki, James W Freeman. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancerMolecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-104
2
P.T.P. Kaumaya, T. Bekaii-Saab. Comprehensive Medicinal Chemistry III2017; : 1 doi: 10.1016/B978-0-12-409547-2.12422-9
3
Mert Erkan, Tania Brocks, Helmut Friess. Cancer Targeted Drug Delivery2013; : 309 doi: 10.1007/978-1-4614-7876-8_12
4
J. Al Shemaili, E. Mensah-Brown, K. Parekh, S.A. Thomas, S. Attoub, B. Hellman, F. Nyberg, A. Adem, P. Collin, T.E. Adrian. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancerEuropean Journal of Cancer 2014; 50(7): 1391 doi: 10.1016/j.ejca.2014.01.002
5
Daniela L. Papademetrio, María Noé Garcia, Daniel Grasso, Élida Alvarez. Autophagy-Mediated Exosomes as Immunomodulators of Natural Killer Cells in Pancreatic Cancer MicroenvironmentFrontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.622956
6
Lauren A. Mauro, Joseph M. Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology2014; : 1397 doi: 10.1016/B978-1-4557-2865-7.00081-3
7
Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Yi Zhang, Hongyan Zhu, Tianqing Liu. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic CancerPharmaceutics 2021; 13(9): 1493 doi: 10.3390/pharmaceutics13091493
8
Libin Wang, Feng Wang, Li Na, Jingjing Yu, Liya Huang, Zhi-Qiang Meng, Zhen Chen, Hao Chen, Liu-Lu Ming, Yong-Qiang Hua. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinomaCancer Biomarkers 2018; 22(1): 169 doi: 10.3233/CBM-181182
9
Yun Wang, Liankang Sun, Yumei Luo, Shuixiang He. Knockdown of KDM1B inhibits cell proliferation and induces apoptosis of pancreatic cancer cellsPathology - Research and Practice 2019; 215(5): 1054 doi: 10.1016/j.prp.2019.02.014
10
Weiliang Jiang, Senlin Zhao, Ling Xu, Yingying Lu, Zhanjun Lu, Congying Chen, Jianbo Ni, Rong Wan, Lijuan Yang. The inhibitory effects of xanthohumol, a prenylated chalcone derived from hops, on cell growth and tumorigenesis in human pancreatic cancerBiomedicine & Pharmacotherapy 2015; 73: 40 doi: 10.1016/j.biopha.2015.05.020
11
Nilanjana Tewari, Abed M Zaitoun, Arvind Arora, Srinivasan Madhusudan, Mohammad Ilyas, Dileep N Lobo. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarraysBMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-436
12
Xiong Zhang, Fen-Shu Jin, Li-Guo Zhang, Rui-Xue Chen, Jin-Hui Zhao, Yan-Nan Wang, En-Fu Wang, Zhen-Dong Jiang. Predictive and Prognostic Roles of Ribonucleotide Reductase M1 in Patients with Pancreatic Cancer Treated with Gemcitabine: A Meta-analysisAsian Pacific Journal of Cancer Prevention 2013; 14(7): 4261 doi: 10.7314/APJCP.2013.14.7.4261
13
Brian Herbst, Lei Zheng. Precision medicine in pancreatic cancer: treating every patient as an exceptionThe Lancet Gastroenterology & Hepatology 2019; 4(10): 805 doi: 10.1016/S2468-1253(19)30175-X
14
Violetta Krajka-Kuźniak, Marta Cykowiak, Hanna Szaefer, Robert Kleszcz, Wanda Baer-Dubowska. Combination of xanthohumol and phenethyl isothiocyanate inhibits NF-κB and activates Nrf2 in pancreatic cancer cellsToxicology in Vitro 2020; 65: 104799 doi: 10.1016/j.tiv.2020.104799
15
Joo Kyung Park, Yejin Kim, Hyemin Kim, Jane Jeon, Tae Wan Kim, Ji-Hong Park, Young-il Hwnag, Wang Jae Lee, Jae Seung Kang. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinomaOncotarget 2016; 7(46): 75081 doi: 10.18632/oncotarget.12057
16
Divya Thomas, Prakash Radhakrishnan. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosisMolecular Cancer 2019; 18(1) doi: 10.1186/s12943-018-0927-5
17
Tianjiao Wang, Zhumei Zhuang, Peng Zhang, Yueyue Wang, Lin Mu, Haifeng Jin, Lei Zhou, Xiaochi Ma, Rui Liang, Yuhui Yuan. Effect of arenobufagin on human pancreatic carcinoma cellsOncology Letters 2017; 14(4): 4971 doi: 10.3892/ol.2017.6798
18
Arnav Bhattacharya, Anirudh Santhoshkumar, Hiroshi Kurahara, Sitaram Harihar. Metastasis Suppressor Genes in Pancreatic CancerPancreas 2021; 50(7): 923 doi: 10.1097/MPA.0000000000001853
19
V Coothankandaswamy, S Cao, Y Xu, P D Prasad, P K Singh, C P Reynolds, S Yang, J Ogura, V Ganapathy, Y D Bhutia. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancerBritish Journal of Pharmacology 2016; 173(23): 3292 doi: 10.1111/bph.13616
20
Chao Tu, Feng Zheng, Jin-Yu Wang, Yuan-Yuan Li, Ke-Qing Qian. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?Asian Pacific Journal of Cancer Prevention 2015; 16(14): 5681 doi: 10.7314/APJCP.2015.16.14.5681
21
Wilson Petrushnko, Justin S. Gundara, Philip R. De Reuver, Greg O'Grady, Jaswinder S. Samra, Anubhav Mittal. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinomaHPB 2016; 18(8): 652 doi: 10.1016/j.hpb.2016.05.004
22
Wen Shi, Sunny M. Ogbomo, Nilesh K. Wagh, Zhengyuan Zhou, Yinnong Jia, Susan K. Brusnahan, Jered C. Garrison. The influence of linker length on the properties of cathepsin S cleavable 177Lu-labeled HPMA copolymers for pancreatic cancer imagingBiomaterials 2014; 35(22): 5760 doi: 10.1016/j.biomaterials.2014.03.056
23
Qingxi Yue, Guogang Gao, Gangyong Zou, Haiqing Yu, Xi Zheng. Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and AdvancementsBioMed Research International 2017; 2017: 1 doi: 10.1155/2017/8412508
24
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Kiyokazu Hiwatashi, Yota Kawasaki, Takaaki Arigami, Sumiya Ishigami, Yuko Kijima, Hiroyuki Shinchi, Sonshin Takao, Shoji Natsugoe. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapyPancreatology 2015; 15(6): 688 doi: 10.1016/j.pan.2015.09.015
25
Gerardo G Mackenzie, Lauren E Bartels, Gang Xie, Ioannis Papayannis, Ninche Alston, Kvetoslava Vrankova, Nengtai Ouyang, Basil Rigas. A Novel Ras Inhibitor (MDC-1016) Reduces Human Pancreatic Tumor Growth in MiceNeoplasia 2013; 15(10): 1184 doi: 10.1593/neo.131368
26
Domenico Ciliberto, Cirino Botta, Pierpaolo Correale, Marco Rossi, Michele Caraglia, Pierfrancesco Tassone, Pierosandro Tagliaferri. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trialsEuropean Journal of Cancer 2013; 49(3): 593 doi: 10.1016/j.ejca.2012.08.019
27
Dingyuan Luo, Matthew G Digiovanni, Ran Wei, Joseph F Lacomb, Jennie L Williams, Basil Rigas, Gerardo G Mackenzie. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabineCarcinogenesis 2020; 41(7): 927 doi: 10.1093/carcin/bgz170
28
Hong He, Hiroshi Maruta. Paks, Rac/Cdc42 (p21)-activated Kinases2013; : 23 doi: 10.1016/B978-0-12-407198-8.00002-3
29
Aimin Cai, Hailun Zheng, Zhiwei Chen, Xinlu Lin, Chen Li, Qing yao, Yangzom D. Bhutia, Vadivel Ganapathy, Ruijie Chen, Longfa Kou. Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cellsBiochemical Journal 2020; 477(10): 1923 doi: 10.1042/BCJ20200275
30
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Hiroyuki Shinchi, Shoji Natsugoe. Prediction of Postoperative Early Recurrence and Prognosis in Pancreatic Cancer PatientsInternational Surgery 2017; 102(5-6): 272 doi: 10.9738/INTSURG-D-17-00072.1
31
Qiu‐Rui He, Jiang‐Jiang Tang, Yao Liu, Zhi‐Fan Chen, Yu‐Xi Liu, Huang Chen, Ding Li, Zheng‐Fang Yi, Jin‐Ming Gao. The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancerBritish Journal of Pharmacology 2021; 178(12): 2496 doi: 10.1111/bph.15435
32
Franziska Brandes, Katharina Schmidt, Christine Wagner, Julia Redekopf, Hans Jürgen Schlitt, Edward Kenneth Geissler, Sven Arke Lang. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer modelBMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1064-9
33
Joseph Markowitz, Taylor R. Brooks, Megan C. Duggan, Bonnie K. Paul, Xueliang Pan, Lai Wei, Zachary Abrams, Eric Luedke, Gregory B. Lesinski, Bethany Mundy-Bosse, Tanios Bekaii-Saab, William E. Carson. Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of diseaseCancer Immunology, Immunotherapy 2015; 64(2): 149 doi: 10.1007/s00262-014-1618-8
34
De-Jun Liu, Yue-Xia Xie, Xiao-Xing Liu, Yan-Miao Huo, Min-Wei Yang, Xue-Liang Fu, Wei Liu, Jian-Yu Yang, Jiao Li, Rong Hua, Pei-Feng Liu, Yong-Wei Sun, Jun-Feng Zhang. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinomaCell Cycle 2017; 16(17): 1622 doi: 10.1080/15384101.2017.1356510
35
Minami Hashimoto, Takuto Hikichi, Tomohiro Suzuki, Mayumi Tai, Osamu Ichii, Nobuo Matsuhashi, Eisaku Kita, Shintaro Takahashi, Yoshinori Okubo, Hando Hakozaki, Yutaka Ejiri, Hiromasa Ohira. Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinomaClinical Journal of Gastroenterology 2017; 10(6): 564 doi: 10.1007/s12328-017-0785-5
36
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Yuko Kijima, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology 2018; 25(5): 1432 doi: 10.1245/s10434-018-6357-1
37
Mingxia Lu, Yu‐Kai Wang, Jiacheng Zhao, Hongxu Lu, Martina H. Stenzel, Pu Xiao. PEG Grafted‐Nanodiamonds for the Delivery of GemcitabineMacromolecular Rapid Communications 2016; 37(24): 2023 doi: 10.1002/marc.201600344
38
Naveen A. Mallangada, Joselin M. Vargas, Swaroopa Thomas, Matthew G. DiGiovanni, Brandon M. Vaeth, Matthew D. Nemesure, Ruixue Wang, Joseph F. LaComb, Jennie L. Williams, Lorne M. Golub, Francis Johnson, Gerardo G. Mackenzie. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting RasMolecular Carcinogenesis 2018; 57(9): 1130 doi: 10.1002/mc.22830
39
Ana De Jesus-Acosta, Amol Narang, Lauren Mauro, Joseph Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology2020; : 1342 doi: 10.1016/B978-0-323-47674-4.00078-5
40
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Takaaki Arigami, Shinichiro Mori, Shinichi Ueno, Hiroyuki Shinchi, Sonshin Takao, Shoji Natsugoe. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinomaPancreatology 2016; 16(6): 1051 doi: 10.1016/j.pan.2016.09.014
41
Hye-Mi Ahn, Dong-Gun Kim, Youn-Jae Kim. Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cellsBiochemical and Biophysical Research Communications 2020; 527(2): 568 doi: 10.1016/j.bbrc.2020.04.118
42
Yan Li, JinWoo Hong, Joung-Eun Oh, A-Rum Yoon, Chae-Ok Yun. Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancerInternational Journal of Cancer 2018; 142(2): 392 doi: 10.1002/ijc.31060
43
Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, Igor Bazin, Elena Poddubskaya, Nebojsa Manojlovic, Dejan Radenkovic, Chris Verslype, Eric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerInternational Journal of Cancer 2018; 143(8): 2053 doi: 10.1002/ijc.31603
44
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Hiroyuki Shinchi, Shoji Natsugoe. Impact of p53 and PDGFR-β Expression on Metastasis and Prognosis of Patients with Pancreatic CancerWorld Journal of Surgery 2016; 40(8): 1977 doi: 10.1007/s00268-016-3477-2
45
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Kiyonori Tanoue, Satoshi Iino, Yota Kawasaki, Tetsuya Idichi, Takaaki Arigami, Shinichiro Mori, Yoshiaki Shinden, Michiyo Higashi, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe. Lung recurrence and its therapeutic strategy in patients with pancreatic cancerPancreatology 2020; 20(1): 89 doi: 10.1016/j.pan.2019.11.015